Company Market Research Report: Tensive S.r.l.

Company Overview

• Name: Tensive S.r.l.

• Mission: The mission of Tensive is to restore a natural breast to patients who have experienced reconstructive surgery after mastectomy or lumpectomy, aiming to improve their quality of life and avoid recurrent and expensive surgical operations.

• Founded: 2012

• Founders/Key People:

• Sanjay Kakkar, MD, MSc, MPH - Chief Executive Officer

• Federico Martello, Ph.D. - Co-founder, Chief Industrial Officer

• Alessandro Tocchio, Ph.D. - Co-founder, Chief Strategy Officer

• Valentina Morigi, MSc - Co-founder, Chief Financial Officer

• Irini Gerges, Ph.D. - Co-founder, Chief Technology Officer and R&D Director

• Margherita Tamplenizza, Ph.D. - Co-founder, Chief Regulatory Officer

• Alberto Cantaluppi, MD - Chief Medical Officer

• Headquarters: Viale Ortles 22/4, 20139, Milano, Italy

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Developing innovative scaffolds for natural breast reconstruction or augmentation using biodegradable synthetic biomaterials.

Products

• REGENERA:

• High-level Description: REGENERA is a biodegradable implant based on a synthetic polymeric scaffold designed for breast reconstruction or augmentation.

• Key Features:

• Designed to naturally restore breast tissue.

• Developed for patients who have had a lumpectomy or mastectomy.

• Provides a minimally invasive, single-surgery solution that can be potentially cost-saving.

• The polymeric scaffold allows for tissue self-regeneration.

• Aims to reduce the psychological impact on patients by restoring a natural breast appearance.

Recent Developments

• Clinical Trials:

• Tensive has announced a multicenter clinical trial across Italy and Spain to assess the safety and performance of REGENERA in patients undergoing reconstructive surgery post-lumpectomy for malignant breast lesions.

• This trial is a major step towards commercialization and offers a promising solution for patient recovery and quality of life.

• Awards and Recognitions:

• Tensive has been awarded by the European Innovation Council Accelerator, receiving a €2.5 million grant and €6 million in equity investment to support their ongoing clinical trials and commercialization efforts.

• They have also received numerous industry awards and recognitions, such as the Gaetano Marzotto Prize and have been featured in international publications such as Wired and Forbes.

• Media Coverage:

• Cited by La Repubblica in connection with developments in biodegradable prosthetics in breast reconstructive surgery.

• Financial Development:

• Through the EIC Accelerator award, Tensive aims to leverage this recognition to attract further investors and venture capitalists for market entry acceleration and commercialization.

Contacts

• General Information: info@tensivemed.com

• Careers: careers@tensivemed.com

• Media Relations: media@tensivemed.com